IP Library Granted Patent US 8,083,663
Granted Patent B2
US 8,083,663 · App. 12/486,492 · Granted Dec 27, 2011

Pelvic disorder treatment

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,083,663
App. No.
12/486,492
Granted
Dec 27, 2011
Kind
B2
Abstract

In a method of treating urinary incontinence, fecal incontinence, constipation and/or pathological retention of urine, at least one electrode of a lead is implanted in contact with a pelvic muscle of the patient. A proximal end of the lead is connected to a hermetically sealed implantable stimulator device configured to apply an electrical waveform through the at least one electrode. The electrical waveform is delivered from the stimulator device to the pelvic muscle through the lead and the at least one electrode. The electrical waveform provides at least partial relief from at least one of urinary incontinence, fecal incontinence, constipation and pathological urine retention.

Claims (28)

1. A method comprising:

providing a lead comprising at least one electrode;

implanting the at least one electrode of the lead in contact with a pelvic muscle of the patient;

connecting a proximal end of the lead to a hermetically sealed implantable stimulator device;

implanting the stimulator device within the patient; and

delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode;

treating a condition of the patient responsive to delivering the electrical waveform, wherein the condition of the patient is selected from the group consisting of fecal incontinence and pathological urine retention.

2. The method of claim 1 , wherein providing a lead comprising at least one electrode comprises providing a lead comprising two or more electrodes.

3. The method of claim 1 , wherein providing a lead comprising at least one electrode comprises providing a lead comprising a fixation device comprising one of a spiral and a hook configured to anchor the lead to the pelvic muscle of the patient.

4. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering a biphasic electrical waveform to the pelvic muscle through the lead and the at least one electrode.

5. The method of claim 1 , wherein providing a lead comprising at least one electrode comprises providing a lead comprising at least one electrode is-selected from the group consisting of an electrode formed from a wire, an electrode in the shape of a spiral and an electrode in the shape of a hook.

6. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering an electrical waveform comprising electrical pulses having a frequency range of 5-200 Hz.

7. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering an electrical waveform comprising electrical pulses having a voltage amplitude in the range of 9-15 volts.

8. The method of claim 1 , wherein treating a condition of the patient responsive to delivering the electrical waveform comprises treating fecal incontinence of the patient responsive to delivering the electrical waveform.

9. The method of claim 1 , wherein treating a condition of the patient responsive to delivering the electrical waveform comprises treating pathological urine retention of the patient responsive to delivering the electrical waveform.

10. The method of claim 1 , further comprising contracting the pelvic muscle responsive to delivering the electrical waveform from.

11. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering an electrical waveform comprising a plurality of pulses each having a pulse width duration of 2 ms or less.

12. A method for treatment of urinary incontinence comprising:

providing a device comprising at least one electrode, a first processor and a second processor;

positioning the at least one electrode to cause contraction of a pelvic muscle of a patient responsive to application of electrical energy to the electrode;

sensing signals selected from the group consisting of electromyogram (EMG) signals from the patient and signals representative of a physiological parameter of the patient;

processing the signals using the first processor at a first data analysis rate;

determining that the signals are indicative of a imminent urinary incontinence based upon processing the signals;

analyzing the signals at a second data analysis rate using the second processor responsive to determining that the signals are indicative of a imminent urinary incontinence, wherein the second data analysis rate is higher than the first data analysis rate; and

applying an electrical waveform to the electrode using the second processor that stimulates the muscle to contract, so as to inhibit the incontinence, responsive to processing the signals.

13. The method of claim 12 , further comprising storing the signals in a queue before analyzing the signals at a second data analysis rate.

14. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering an electrical waveform comprising electrical pulses having a frequency range of 20-50 Hz.

15. The method of claim 1 , wherein delivering an electrical waveform from the stimulator device to the pelvic muscle through the lead and the at least one electrode comprises delivering an electrical waveform comprising electrical pulses having a frequency range of 20-30 Hz.

Assignments (15)
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Sep 17, 2021
From: ASTORA WOMEN'S HEALTH LLC; ENDO PHARMACEUTICALS SOLUTIONS INC.; ENDO PHARMACEUTICALS INC.; PAR PHARMACEUTICAL, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 057538/0978 →
SECURITY INTEREST Recorded Jun 8, 2017
From: ASTORA WOMEN'S HEALTH, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL TRUSTEE
Reel/Frame 042743/0278 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CONVEYING PARTY NAME PREVIOUSLY RECORDED AT REEL: 037300 FRAME: 0607. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 11, 2016
From: AMS RESEARCH CORPORATION
To: AMS RESEARCH, LLC
Reel/Frame 037514/0402 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2016
From: AMS RESEARCH, LLC
To: APHRODITE WOMEN'S HEALTH, LLC
Reel/Frame 037473/0425 →
CHANGE OF NAME Recorded Jan 11, 2016
From: APHRODITE WOMEN'S HEALTH, LLC
To: ASTORA WOMEN'S HEALTH, LLC
Reel/Frame 037473/0535 →
CHANGE OF NAME Recorded Dec 15, 2015
From: AMS RESEARCH CORPATION
To: AMS RESEARCH, LLC
Reel/Frame 037300/0607 →
RELEASE OF SECURITY INTEREST Recorded Aug 6, 2015
From: DEUTSCHE BANK AG NEW YORK BRANCH
To: AMERICAN MEDICAL SYSTEMS, LLC; AMS RESEARCH, LLC; LASERSCOPE
Reel/Frame 036285/0146 →
GRANT OF SECURITY INTEREST IN PATENTS Recorded Mar 20, 2014
From: ENDO PHARMACEUTICALS SOLUTIONS, INC.; ENDO PHARMACEUTICALS, INC.; AMS RESEARCH CORPORATION; AMERICAN MEDICAL SYSTEMS, INC.; LASERSCOPE
To: DEUTSCHE BANK AG NEW YORK BRANCH, AS COLLATERAL AGENT
Reel/Frame 032491/0440 →
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: AMS RESEARCH CORPORATION
Reel/Frame 032380/0053 →
SECURITY AGREEMENT Recorded Jul 22, 2011
From: AMS RESEARCH CORPORATION
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026632/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: LIFSCHITZ, DAVID; NISSENKORN, ISRAEL
To: LIFSCHITZ & COMPANY
Reel/Frame 025974/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2011
From: LIFSCHITZ AND COMPANY
To: BIO CONTROL MEDICAL LTD.
Reel/Frame 025974/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2011
From: BIO CONTROL MEDICAL (B.C.M.) LTD.
To: AMS RESEARCH CORPORATION
Reel/Frame 025959/0477 →